Genedx Holdings (WGS) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Genedx Holdings Corp   (NASDAQ: WGS)

Select the Financial Report: Select the Period:


Description of Genedx Holdings's Business Segments


GeneDx Holdings Corp. was primarily focused on genetic testing and related services. GeneDx specializes in providing a wide range of genetic testing solutions that cater to various medical and healthcare needs. Below is a detailed description of the segments, products, and services offered by GeneDx:

Segments

1. Clinical Genetic Testing:
- Carrier Screening: Testing to determine if an individual carries a gene for a specific genetic disorder, which can be critical for family planning.
- Diagnostic Testing: Testing conducted to confirm or rule out a specific genetic condition in patients showing symptoms.
- Exome Sequencing: Comprehensive examination of the protein-coding regions of genes to identify mutations that could lead to genetic disorders.

2. Prenatal Testing:
- Non-Invasive Prenatal Testing (NIPT): A blood test that assesses the risk of certain genetic conditions in a fetus, offering early insights into potential disorders.

3. Specialty Genetic Testing:
- Aimed at specific areas such as oncology, cardiovascular conditions, and rare diseases, these tests provide targeted insights that are crucial for treatment decisions.

4. Pharmacogenomics:
- A segment that assesses how genetic variations impact an individuals response to specific medications, allowing healthcare providers to tailor treatments based on genetic profiles.

Products

1. Genetic Test Panels:
- Comprehensive panels that assess multiple genes associated with a particular condition or set of conditions.
- Designed for specific disorders, including but not limited to cardiovascular diseases, neurological disorders, and cancer predisposition syndromes.

2. Whole Exome Sequencing (WES):
- This product focuses on sequencing all coding regions of genes, giving clinicians a broad overview of potential genetic anomalies.

3. Whole Genome Sequencing (WGS):
- An advanced product that analyzes the entire genome, providing the most exhaustive genetic information available.

4. Variant Interpretation Tools:
- Software and analytic tools that help doctors understand the clinical significance of genetic variants identified in testing.

Services

1. Genetic Counseling:
- GeneDx offers access to genetic counselors who provide expert guidance to patients and families. This service helps interpret test results and understand the implications for health, wellness, and family planning.

2. Clinical Support Services:
- Dedicated support for healthcare providers in interpreting results, making informed decisions, and integrating genetic testing into patient care.

3. Research and Development Services:
- Collaborations with research institutions and pharmaceutical companies to advance genetic research, improve testing methodologies, and contribute to the understanding of genetic diseases.

4. Educational Resources:
- Providing educational tools and materials for healthcare providers and patients to better understand genetic testing and its importance.

Conclusion

GeneDx Holdings Corp. is deeply entrenched in the genetic testing industry, offering a robust portfolio of tests designed to meet a variety of clinical needs—from carrier and prenatal screening to diagnostic services and pharmacogenomics. Their services are tailored toward enhancing clinical outcomes, supporting healthcare professionals, and improving patient understanding of genetic health. This strategic focus positions GeneDx at the forefront of precision medicine, playing a crucial role in the evolving landscape of genomic healthcare.


Composition of Genedx Holdings Corp Revenues by Segments

 
GeneDx    99.3 % of total Revenue
Other    0.74 % of total Revenue
Diagnostic test revenue    99.11 % of total Revenue
Diagnostic test revenue GeneDx    98.55 % of total Revenue
Diagnostic test revenue Other    0.55 % of total Revenue
Patients with third-party insurance    83.08 % of total Revenue
Patients with third-party insurance GeneDx    83.08 % of total Revenue
Institutional customers    15.75 % of total Revenue
Institutional customers GeneDx    15.19 % of total Revenue
Institutional customers Other    0.55 % of total Revenue
Self-pay patients    0.28 % of total Revenue
Self-pay patients GeneDx    0.28 % of total Revenue
Other GeneDx    0.75 % of total Revenue
Other Other    0.19 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
GeneDx 101.50 99.3 %
Other 0.76 0.74 %
Diagnostic test revenue 101.30 99.11 %
Diagnostic test revenue GeneDx 100.73 98.55 %
Diagnostic test revenue Other 0.57 0.55 %
Patients with third-party insurance 84.92 83.08 %
Patients with third-party insurance GeneDx 84.92 83.08 %
Institutional customers 16.09 15.75 %
Institutional customers GeneDx 15.53 15.19 %
Institutional customers Other 0.57 0.55 %
Self-pay patients 0.29 0.28 %
Self-pay patients GeneDx 0.29 0.28 %
Other GeneDx 0.76 0.75 %
Other Other 0.19 0.19 %
Total 102.21 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
GeneDx 16.51 % -
Other -44.1 % -
Diagnostic test revenue 18.12 % -
Diagnostic test revenue GeneDx 17.46 % -
Diagnostic test revenue Other - -
Patients with third-party insurance 24.77 % -
Patients with third-party insurance GeneDx 24.77 % -
Institutional customers -8.58 % -
Institutional customers GeneDx -11.79 % -
Institutional customers Other - -
Self-pay patients 197.92 % -
Self-pay patients GeneDx 197.92 % -
Other GeneDx -43.73 % -
Other Other - -
Total 18.2 % -76.07 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total -63.32 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Genedx Holdings Corp Divisions, Sales by Country

 
GeneDx   GeneDx Segment contribution to total sales 99.04 % of total Revenue
Other   Other Segment contribution to total sales 1.04 % of total Revenue
Diagnostic test revenue   Diagnostic test revenue Segment contribution to total sales 97.54 % of total Revenue
Diagnostic test revenue GeneDx   Diagnostic test revenue GeneDx Segment contribution to total sales 97.3 % of total Revenue
Diagnostic test revenue Other   Diagnostic test revenue Other Segment contribution to total sales 0.24 % of total Revenue
Patients with third-party insurance   Patients with third-party insurance Segment contribution to total sales 80.82 % of total Revenue
Patients with third-party insurance GeneDx   Patients with third-party insurance GeneDx Segment contribution to total sales 80.82 % of total Revenue
Institutional customers   Institutional customers Segment contribution to total sales 16.4 % of total Revenue
Institutional customers GeneDx   Institutional customers GeneDx Segment contribution to total sales 16.16 % of total Revenue
Institutional customers Other   Institutional customers Other Segment contribution to total sales 0.24 % of total Revenue
Self-pay patients   Self-pay patients Segment contribution to total sales 0.32 % of total Revenue
Self-pay patients GeneDx   Self-pay patients GeneDx Segment contribution to total sales 0.32 % of total Revenue
Other GeneDx   Other GeneDx Segment contribution to total sales 1.74 % of total Revenue
Other Other   Other Other Segment contribution to total sales 0.8 % of total Revenue


Twelve months ended 2025
WGS s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
GeneDx 423.09 99.04 %
Other 4.45 1.04 %
Diagnostic test revenue 416.67 97.54 %
Diagnostic test revenue GeneDx 415.64 97.3 %
Diagnostic test revenue Other 1.03 0.24 %
Patients with third-party insurance 345.24 80.82 %
Patients with third-party insurance GeneDx 345.24 80.82 %
Institutional customers 70.07 16.4 %
Institutional customers GeneDx 69.05 16.16 %
Institutional customers Other 1.03 0.24 %
Self-pay patients 1.36 0.32 %
Self-pay patients GeneDx 1.36 0.32 %
Other GeneDx 7.45 1.74 %
Other Other 3.42 0.8 %
Total 427.17 100 %


Twelve months ended 2025
WGS s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -21.02 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
GeneDx 39.96 % -
Other 40.99 % -
Diagnostic test revenue 37.9 % -
Diagnostic test revenue GeneDx 39.01 % -
Diagnostic test revenue Other -67.47 % -
Patients with third-party insurance 47.1 % -
Patients with third-party insurance GeneDx 49.1 % -
Institutional customers 7.61 % -
Institutional customers GeneDx 6.04 % -
Self-pay patients -41.91 % -
Self-pay patients GeneDx -41.91 % -
Other GeneDx 126.15 % -
Total 39.87 % -
Patients with third-party insurance Other - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.